Phase I Study Involving Gadolinium Texaphyrin (NSC 695238) in Patients With Pancreatic and Periampullary Adenocarcinoma Receiving Radiotherapy for Unresectable Disease.
Phase of Trial: Phase I
Latest Information Update: 23 May 2018
At a glance
- Drugs Motexafin gadolinium (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Periampullary cancer
- Focus Adverse reactions
- 17 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.